AntibioticDB

Highest development stage: Phase 4 (NCT02452918)

Development status: Approved

Gram-positive activity

Mechanism of Action/Target pathogen: Approved for: acute bacterial skin and skin structure infections (ABSSSI) caused by Gram- positive bacteria, including methicillin- resistant Staphylococcus aureus (MRSA)

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10877

Source: https://journals.asm.org/doi/epdf/10.1128/aac.40.9.2194

Citation (1): http://aac.asm.org/content/58/5/2921.full

Citation (2): https://www.jstage.jst.go.jp/article/antibiotics1968/49/6/49_6_575/_pdf

Citation (3): https://www.pnas.org/doi/10.1073/pnas.0931492100#sec-2

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/16136912

Oritavancin (Orbactiv), LY333328

Glycopeptide

The Medicines Company, USA

1996